Lilly names Patrik Jonsson to lead diabetes and obesity unit as Mike Mason retires

Eli Lilly said Wednesday that Mike Mason will retire from his role as head of the company's diabetes and obesity division, and that Patrik Jonsson, currently president of Lilly USA, will take on those responsibilities beginning Jan. 1 ^[1]. Mason oversaw late-stage development and the launch of Mounjaro, the brand name for tirzepatide ^[1].

The announcement came as Lilly awaits a regulatory decision on using tirzepatide as a weight-loss treatment ^[1][2]. Mounjaro is already prescribed by doctors off-label for obesity ^[1]. The drug recorded $979.7 million in sales in the latest quarter, and Lilly's shares had gained about 44% so far this year, driven by investor expectations for it ^[1]. The company reported $29 billion in sales in 2022 and $15 billion in the first six months of 2023 ^[2].

Jonsson, who has spent 33 years at Lilly and has led its immunology unit and operations in Sweden, Scandinavia, Italy and Japan, will oversee the company's launched products and late-stage development in diabetes and obesity ^[1]. That portfolio includes tirzepatide along with retatrutide, a next-generation obesity drug, and orforglipron, an obesity pill ^[1]. BioPharma Dive reported that Jonsson also served as chief customer officer ^[2].

Mason spent more than three decades at Lilly and held roles in its neurosciences and diabetes divisions, taking the division's top job four years ago after the departure of Enrique Conterno ^[2]. "I have worked with Mike throughout most of my career at Lilly and can attest to the broad and positive impact he has had on our company," CEO David Ricks said in a statement ^[2].

The changes extended beyond the diabetes and obesity unit. Lilly's chief scientific officer, Daniel Skovronsky, will add leadership of the immunology division to his responsibilities ^[1][2]. Jennifer Oleksiw, currently chief consumer experience officer, will become chief customer officer and report to Ricks ^[2]. David Hyman, oncology chief medical officer, will take that role across the entire company, and Mark Genovese, most recently at Gilead Sciences, will become senior vice president leading mid- and late-stage clinical development in inflammation ^[2].

BioPharma Dive noted the leadership moves arrive at a mixed moment for Lilly: the company has seen its valuation climb on clinical and commercial successes, and its biologic drug donanemab could win FDA clearance later this year, but the agency also rejected two experimental inflammation drugs in 2023 over manufacturing problems ^[2].

Why it matters for patients

Who runs Lilly's cardiometabolic business affects the drugs patients are already taking or considering. Tirzepatide is used for type 2 diabetes under the Mounjaro brand and is prescribed off-label for weight loss ^[1]. If regulators clear it for obesity, demand could rise sharply, and the division's leadership will shape manufacturing, supply and how the drug is marketed to clinicians and patients.

Jonsson's portfolio also includes retatrutide and orforglipron, an experimental oral obesity drug, meaning the same executive will make decisions about which programs get priority and resources ^[1]. Patients waiting on oral GLP-1 options or newer injectables have an interest in how those choices are made, though no timeline for either drug's approval has been disclosed.

The market context is large: GLP-1 drugs, which stimulate insulin production, have started a weight-loss market estimated to reach $100 billion within a decade ^[1]. That scale is one reason Lilly is reorganizing leadership now rather than later.

What happens next

Mason's retirement and Jonsson's new responsibilities take effect Jan. 1 ^[1]. The FDA decision on tirzepatide for obesity is expected, but the timing of that decision has not been reported ^[1][2]. Lilly has not disclosed a date for a decision on retatrutide or orforglipron ^[1].